Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 200 articles:
HTML format



Single Articles


    July 2022
  1. BADAR T, Atallah E, Shallis RM, Goldberg AD, et al
    Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
    Am J Hematol. 2022;97:E232-E235.
    PubMed    


    June 2022
  2. DHOPESHWARKAR N, Yang W, Hennessy S, Rhodes JM, et al
    Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26632.
    PubMed    


  3. JABBOUR EJ, Short NJ, Jain N, Jammal N, et al
    Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10(-4) and Higher.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
    PubMed     Abstract available


  4. TEFFERI A, Gangat N, Al-Kali A, Alkhateeb H, et al
    A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
    Am J Hematol. 2022 Jun 15. doi: 10.1002/ajh.26630.
    PubMed     Abstract available


  5. BARON F, Labopin M, Tischer J, Ciceri F, et al
    Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients >/=55 years of age.
    Am J Hematol. 2022 Jun 13. doi: 10.1002/ajh.26627.
    PubMed     Abstract available


    May 2022
  6. PAUL S, Kantarjian H, Sasaki K, Marx K, et al
    Intrathecal Prophylaxis with 12 Versus 8 Administrations Reduces the Incidence of Central Nervous System Relapse in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 28. doi: 10.1002/ajh.26622.
    PubMed    


  7. BEELEN DW, Stelljes M, Remenyi P, Wagner-Drouet EM, et al
    Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26620.
    PubMed     Abstract available


  8. VABRE C, Zelmat Y, Gauthier M, Pajiep M, et al
    Incident users of tyrosine kinase inhibitors in chronic myeloid leukemia patients: analysis of anticancer treatment trajectories - A French population-based study using the French national health data system.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26621.
    PubMed    


  9. GAMBACORTI-PASSERINI C, Nicolini FE, Larson RA, Aroldi A, et al
    Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
    Am J Hematol. 2022 May 23. doi: 10.1002/ajh.26618.
    PubMed    


  10. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2022 May 18. doi: 10.1002/ajh.26601.
    PubMed     Abstract available


  11. JONAS BA, Wei AH, Recher C, DiNardo CD, et al
    Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26600.
    PubMed    


  12. CHERNG HJ, Khwaja R, Kanagal-Shamanna R, Tang G, et al
    TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26595.
    PubMed     Abstract available


  13. GOTTLIEB DJ, Sutrave G, Jiang W, Avdic S, et al
    Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant.
    Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26594.
    PubMed     Abstract available


  14. SINGH A, Al-Kali A, Begna KH, Litzow MR, et al
    Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Am J Hematol. 2022;97:630-637.
    PubMed     Abstract available


  15. WANG J, Zhang X, Zhou Z, Liu Y, et al
    A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
    PubMed     Abstract available


  16. GORDON MJ, Ferrajoli A
    Unusual complications in the management of chronic lymphocytic leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26585.
    PubMed     Abstract available


    April 2022
  17. PEREZ-CARRETERO C, Hernandez-Sanchez M, Gonzalez T, Quijada-Alamo M, et al
    TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26578.
    PubMed     Abstract available


  18. KIM K, Konopleva M, DiNardo CD, Borthakur G, et al
    Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
    Am J Hematol. 2022 Apr 12. doi: 10.1002/ajh.26572.
    PubMed     Abstract available


  19. TANG B, Lee JB, Cheng S, Pan T, et al
    Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study.
    Am J Hematol. 2022 Apr 6. doi: 10.1002/ajh.26564.
    PubMed    


  20. SASAKI K, Ravandi F, Kadia T, DiNardo C, et al
    Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26557.
    PubMed     Abstract available


  21. INZOLI E, Aroldi A, Piazza R, Gambacorti-Passerini C, et al
    Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26556.
    PubMed     Abstract available


  22. LARSSON K, Soderling J, Hoglund M, Glimelius I, et al
    Cardiovascular disease in patients with chronic lymphocytic leukemia. A Swedish nationwide register study with matched comparators.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26558.
    PubMed    


  23. MCLAUGHLIN N, Ruan G, Day CN, Harmsen WS, et al
    A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004-2015.
    Am J Hematol. 2022;97:E144-E147.
    PubMed    


    March 2022
  24. HADDAD FG, Sasaki K, Issa GC, Garcia-Manero G, et al
    Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors.
    Am J Hematol. 2022 Mar 31. doi: 10.1002/ajh.26550.
    PubMed     Abstract available


  25. COOK L, Al-Yousuf H, Mohamedbhai S, Bain BJ, et al
    Hyposplenism in adult T-cell leukemia/lymphoma.
    Am J Hematol. 2022 Mar 26. doi: 10.1002/ajh.26547.
    PubMed    


  26. TORELLI GF, Chiaretti S, Peragine N, Barberi W, et al
    Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.
    Am J Hematol. 2022 Mar 22. doi: 10.1002/ajh.26537.
    PubMed    


  27. KRAKOW EF, Walter RB, Nathe JM, Perez T, et al
    Intensive Chemotherapy for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation.
    Am J Hematol. 2022 Mar 18. doi: 10.1002/ajh.26540.
    PubMed    


  28. SMITH AC, Maze D, Xia D, Capo-Chichi JM, et al
    A t(6;14;9)(p22;q22;q34) Three-Way Translocation: Description of a Cytogenetically Visible Variant t(6;9) in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Mar 16. doi: 10.1002/ajh.26534.
    PubMed    


  29. GALLANT RE, Arroyo K, Bracci PM, Li S, et al
    Clinical characteristics of cytomegalovirus-positive pediatric acute lymphoblastic leukemia at diagnosis.
    Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26528.
    PubMed    


  30. SHORT NJ, Macaron W, Konopleva M, Ravandi F, et al
    Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
    Am J Hematol. 2022 Mar 10. doi: 10.1002/ajh.26526.
    PubMed    


  31. KENNEDY VE, Hui G, Azenkot T, Gaut D, et al
    Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Mar 9. doi: 10.1002/ajh.26524.
    PubMed    


  32. ORTIZ-MALDONADO V, Alonso-Saladrigues A, Espanol-Rego M, Martinez-Cibrian N, et al
    Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
    Am J Hematol. 2022 Mar 7. doi: 10.1002/ajh.26519.
    PubMed     Abstract available


    February 2022
  33. MOSHREF RAZAVI H, Yu R
    Myeloid neoplasm with PDGFRB rearrangement, presenting as systemic mastocytosis-chronic eosinophilic leukemia.
    Am J Hematol. 2022 Feb 21. doi: 10.1002/ajh.26505.
    PubMed    


  34. POMMERT L, Schafer ES, Malvar J, Gossai N, et al
    Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26510.
    PubMed     Abstract available


  35. ARBER DA, Hasserjian RP, Orazi A, Mathews V, et al
    Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26503.
    PubMed    


  36. BALL S, Jain AG, Aguirre LE, Al Ali N, et al
    Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26504.
    PubMed    


  37. SHI M, Li L, Wang S, Cheng H, et al
    Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26506.
    PubMed     Abstract available


  38. MOLICA S, Giannarelli D, Visentin A, Reda G, et al
    Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
    Am J Hematol. 2022 Feb 16. doi: 10.1002/ajh.26502.
    PubMed    


  39. SENAPATI J, Shoukier M, Garcia-Manero G, Wang X, et al
    Activity of Decitabine as Maintenance Therapy in Core Binding Factor Acute Myeloid Leukemia.
    Am J Hematol. 2022 Feb 12. doi: 10.1002/ajh.26496.
    PubMed     Abstract available


  40. POURHASSAN H, Yang D, Afkhami M, Pillai R, et al
    High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.
    Am J Hematol. 2022 Feb 7. doi: 10.1002/ajh.26490.
    PubMed    


  41. RACK K, De Bie J, Ameye G, Gielen O, et al
    Optimizing the Diagnostic Workflow for Acute Lymphoblastic Leukemia by Optical Genome Mapping.
    Am J Hematol. 2022 Feb 4. doi: 10.1002/ajh.26487.
    PubMed     Abstract available


  42. ALLSUP DJ, Craig Z, Cairns D, Howard D, et al
    Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
    Am J Hematol. 2022 Feb 2. doi: 10.1002/ajh.26483.
    PubMed    


  43. UJJANI C, Greninger AL, Shadman M, Hill JA, et al
    Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Am J Hematol. 2022;97:E67-E69.
    PubMed    


  44. GAO F, Gao Y, Luo Y, Yu J, et al
    Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transpl
    Am J Hematol. 2022;97:E44-E47.
    PubMed    


  45. KUNO M, Yamasaki S, Fujii N, Ishida Y, et al
    Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation.
    Am J Hematol. 2022;97:185-193.
    PubMed     Abstract available


    January 2022
  46. SZUBER N, Elliott M, Tefferi A
    Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.
    Am J Hematol. 2022 Jan 28. doi: 10.1002/ajh.26481.
    PubMed     Abstract available


  47. LAZARIAN G, Theves F, Hormi M, Letestu R, et al
    TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.
    Am J Hematol. 2022 Jan 26. doi: 10.1002/ajh.26479.
    PubMed    


  48. IJURKO C, Gonzalez-Garcia N, Galindo-Villardon P, Hernandez-Hernandez A, et al
    A 29-gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival.
    Am J Hematol. 2022 Jan 24. doi: 10.1002/ajh.26477.
    PubMed     Abstract available


  49. DORFMAN DM, Pinkus GS
    A case of peripheral T-cell lymphoma, NOS mimicking acute monocytic leukemia.
    Am J Hematol. 2022 Jan 22. doi: 10.1002/ajh.26476.
    PubMed    


  50. ROSSI M, Nizzoli ME, Galli A, Roncoroni E, et al
    Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome.
    Am J Hematol. 2022 Jan 18. doi: 10.1002/ajh.26469.
    PubMed    


  51. DAHLEN T, Edgren G, Ljungman P, Flygt H, et al
    Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
    Am J Hematol. 2022 Jan 11. doi: 10.1002/ajh.26463.
    PubMed     Abstract available


  52. JELLOUL FZ, Yang R, Wang P, Garces S, et al
    Non-Coding NOTCH1 Mutations in Chronic Lymphocytic Leukemia Negatively Impact Prognosis.
    Am J Hematol. 2022 Jan 6. doi: 10.1002/ajh.26457.
    PubMed    


  53. PATNAIK MM, Tefferi A
    Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.
    Am J Hematol. 2022 Jan 5. doi: 10.1002/ajh.26455.
    PubMed     Abstract available


  54. REVILLE PK, Sasaki K, Kantarjian HM, Daver NG, et al
    Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26451.
    PubMed     Abstract available


  55. NUMAN Y, Abdel Rahman Z, Grenet J, Boisclair S, et al
    Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26447.
    PubMed     Abstract available


  56. NAGLER A, Labopin M, Craddock C, Socie G, et al
    Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26442.
    PubMed     Abstract available


  57. RIBEIL JA
    Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?
    Am J Hematol. 2022;97:4-6.
    PubMed    


    December 2021
  58. DAVIDS MS, Shadman M, Parikh SA, Ujjani C, et al
    A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.
    Am J Hematol. 2021 Dec 20. doi: 10.1002/ajh.26444.
    PubMed    


  59. VISENTIN A, Mauro FR, Cibien F, Vitale C, et al
    Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
    Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26437.
    PubMed    


  60. SEGOT A, Stalder G, de Leval L, Solly F, et al
    Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.
    Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26436.
    PubMed    


  61. FORTES BH, Dalvin LA, Hogan WJ, Patnaik MM, et al
    Isolated T-cell acute lymphoblastic leukemic optic disc infiltration.
    Am J Hematol. 2021;96:1717-1718.
    PubMed    


    November 2021
  62. SANTOS FM, Ghelfond G, Seguro FS, Abdo ANR, et al
    Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia.
    Am J Hematol. 2021 Nov 25. doi: 10.1002/ajh.26424.
    PubMed    


  63. POPOVIC R, Dunbar F, Lu C, Robinson K, et al
    Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
    Am J Hematol. 2021 Nov 14. doi: 10.1002/ajh.26411.
    PubMed    


  64. CHO BS, Min GJ, Park SS, Yoon SY, et al
    Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
    Am J Hematol. 2021;96:1441-1449.
    PubMed     Abstract available


    October 2021
  65. SASAKI K, Kadia T, Begna K, DiNardo CD, et al
    Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.
    Am J Hematol. 2021 Oct 30. doi: 10.1002/ajh.26395.
    PubMed     Abstract available


  66. TROUSSARD X, Maitre E, Cornet E
    Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26390.
    PubMed     Abstract available


  67. MUCHTAR E, Koehler AB, Johnson MJ, Rabe KG, et al
    Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Am J Hematol. 2021 Oct 26. doi: 10.1002/ajh.26388.
    PubMed     Abstract available


  68. ZHANG Y, Li X, Weng X, Shen Y, et al
    Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: a single-arm, phase 2 trial (RJ-AML 2014).
    Am J Hematol. 2021 Oct 23. doi: 10.1002/ajh.26386.
    PubMed     Abstract available


  69. HALLEK M, Al-Sawaf O
    Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26367.
    PubMed     Abstract available


  70. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
    BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Am J Hematol. 2021;96:1195-1203.
    PubMed     Abstract available


  71. GRIMM J, Jentzsch M, Bill M, Backhaus D, et al
    Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:1287-1294.
    PubMed     Abstract available


    September 2021
  72. FURSTENAU M, Giza A, Stumpf T, Robrecht S, et al
    Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
    Am J Hematol. 2021 Sep 30. doi: 10.1002/ajh.26363.
    PubMed    


    August 2021
  73. SALIBA AN, Litzow MR, Gangat N, Al-Kali A, et al
    Outcomes of Venetoclax-Based Therapy in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2021 Aug 24. doi: 10.1002/ajh.26334.
    PubMed    


  74. ZHOU B, Chu X, Tian H, Liu T, et al
    The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-year Retrospective Study.
    Am J Hematol. 2021 Aug 18. doi: 10.1002/ajh.26324.
    PubMed     Abstract available


  75. ZHANG M, Xiao H, Shi J, Tan Y, et al
    Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: a phase III randomized controlled study.
    Am J Hematol. 2021 Aug 9. doi: 10.1002/ajh.26317.
    PubMed     Abstract available


  76. ALWASH Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, et al
    Development of TP53 Mutations Over the Course of Therapy for Acute Myeloid Leukemia.
    Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.
    PubMed     Abstract available


  77. CHEN Z, Song J, Wang W, Bai J, et al
    A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia.
    Am J Hematol. 2021 Aug 2. doi: 10.1002/ajh.26309.
    PubMed     Abstract available


    July 2021
  78. VARETTONI M, Orlandi E, Zibellini S, Rossi M, et al
    Prognostic impact of somatic mutations on time to first treatment: results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
    Am J Hematol. 2021 Jul 30. doi: 10.1002/ajh.26302.
    PubMed    


  79. KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
    Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
    Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.
    PubMed    


  80. BROCCOLI A, Argnani L, Nanni L, Terragna C, et al
    The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a thirty-year experience.
    Am J Hematol. 2021 Jul 10. doi: 10.1002/ajh.26287.
    PubMed     Abstract available


  81. GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
    Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Am J Hematol. 2021;96:781-789.
    PubMed     Abstract available


  82. HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
    Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
    Am J Hematol. 2021;96:E259-E262.
    PubMed    


  83. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:E237-E239.
    PubMed    


  84. JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
    A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
    Am J Hematol. 2021;96:E226-E229.
    PubMed    


  85. OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
    Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
    Am J Hematol. 2021;96:E223-E225.
    PubMed    


    June 2021
  86. JABBOUR E, Patel K, Jain N, Duose D, et al
    Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
    Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
    PubMed     Abstract available


  87. LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
    Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
    PubMed    


  88. MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
    Ruxolitinib for refractory large granular lymphocyte leukemia.
    Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.
    PubMed    


  89. HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
    Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
    Am J Hematol. 2021;96:E187-E189.
    PubMed    


    May 2021
  90. AL-SAWAF O, Gentile B, Devine J, Zhang C, et al
    Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26260.
    PubMed     Abstract available


  91. PICIOCCHI A, Messina M, Elia L, Vitale A, et al
    Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.
    Am J Hematol. 2021 May 28. doi: 10.1002/ajh.26253.
    PubMed    


  92. ST MARTIN EC, Ferrer A, Wudhikarn K, Mangaonkar A, et al
    Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes.
    Am J Hematol. 2021 May 24. doi: 10.1002/ajh.26250.
    PubMed    


  93. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
    PubMed    


  94. JAIN N, Maiti A, Ravandi F, Konopleva M, et al
    Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia.
    Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.
    PubMed     Abstract available


  95. MORABITO F, Del Poeta G, Mauro FR, Reda G, et al
    TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
    Am J Hematol. 2021 May 14. doi: 10.1002/ajh.26235.
    PubMed    


  96. HALL KH, Brooks A, Waller EK
    Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26231.
    PubMed    


  97. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Am J Hematol. 2021;96:E168-E171.
    PubMed    


  98. OTHMAN TA, Mei M, Zhang J, Aldoss I, et al
    Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Am J Hematol. 2021;96:E140-E143.
    PubMed    


    April 2021
  99. KADIA TM, Ravandi F, Borthakur G, Konopleva M, et al
    Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2021 Apr 26. doi: 10.1002/ajh.26206.
    PubMed     Abstract available


  100. YILMAZ M, Daver N, Borthakur G, Kadia T, et al
    FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
    Am J Hematol. 2021 Apr 23. doi: 10.1002/ajh.26202.
    PubMed    


  101. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
    Am J Hematol. 2021 Apr 20. doi: 10.1002/ajh.26201.
    PubMed    


  102. JAMY O, Godby R, Sarmad R, Costa LJ, et al
    Survival of Chronic Myeloid Leukemia Patients in Comparison to the General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26195.
    PubMed    


  103. PELLAND-MARCOTTE MC, Kulkarni K, Athale UH, Pole JD, et al
    Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C.
    Am J Hematol. 2021 Apr 13. doi: 10.1002/ajh.26193.
    PubMed     Abstract available


  104. APEL A, Moshe Y, Ofran Y, Gural A, et al
    Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice.
    Am J Hematol. 2021 Apr 9. doi: 10.1002/ajh.26190.
    PubMed     Abstract available


  105. DONG N, Castillo Tokumori F, Isenalumhe L, Zhang Y, et al
    Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases.
    Am J Hematol. 2021 Apr 5. doi: 10.1002/ajh.26183.
    PubMed     Abstract available


  106. GANGAT N, Szuber N, Jawaid T, Hanson CA, et al
    Young platelet millionaires with essential thrombocythemia.
    Am J Hematol. 2021;96:E93-E95.
    PubMed    


  107. PARDANANI A
    Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:508-525.
    PubMed     Abstract available


    March 2021
  108. SHORT NJ, Konopleva M, Kadia T, Kebriaei P, et al
    An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Am J Hematol. 2021 Mar 29. doi: 10.1002/ajh.26175.
    PubMed    


  109. AUDIL HY, Hampel PJ, Van Dyke DL, Achenbach SJ, et al
    The Prognostic Significance of del6q23 in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2021 Mar 22. doi: 10.1002/ajh.26168.
    PubMed    


  110. LIU S, Deng B, Yin Z, Lin Y, et al
    Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Am J Hematol. 2021 Mar 16. doi: 10.1002/ajh.26160.
    PubMed     Abstract available


  111. SALHOTRA A, Aribi A, Ngo D, Zhang J, et al
    Outcome of secondary Acute Myeloid Leukemia treated with Hypomethylating agent plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin-Cytarabine (CPX-351).
    Am J Hematol. 2021 Mar 14. doi: 10.1002/ajh.26157.
    PubMed    


  112. SASAKI K, Jabbour E, Short NJ, Jain N, et al
    Acute Lymphoblastic Leukemia: A Population- based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results (SEER) Database, 1980-2017.
    Am J Hematol. 2021 Mar 11. doi: 10.1002/ajh.26156.
    PubMed     Abstract available


  113. BALL BJ, Hsu M, Devlin SM, Arcila M, et al
    The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
    Am J Hematol. 2021 Mar 1. doi: 10.1002/ajh.26146.
    PubMed    


  114. WILHELMSSON M, Jahnukainen K, Winiarski J, Abrahamsson J, et al
    Hospitalizations in long-term survivors of childhood AML treated with allogeneic HCT-An Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.
    Am J Hematol. 2021;96:E74-E77.
    PubMed    


  115. FERNANDES F, Ramalho R, Barreira R, Silveira M, et al
    Large granular lymphocytosis induced by dasatinib.
    Am J Hematol. 2021;96:395-396.
    PubMed    


    February 2021
  116. CHATZIDIMITRIOU C, Pappa V, Lakiotaki E, Plata E, et al
    Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
    Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26145.
    PubMed    


  117. MORITA K, Jain N, Kantarjian H, Takahashi K, et al
    Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine.
    Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26144.
    PubMed     Abstract available


  118. MOU T, Pawitan Y, Stahl M, Vesterlund M, et al
    The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia.
    Am J Hematol. 2021 Feb 24. doi: 10.1002/ajh.26141.
    PubMed     Abstract available


  119. FATHI AT, Stein EM, DiNardo CD, Levis MJ, et al
    Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.
    Am J Hematol. 2021 Feb 24. doi: 10.1002/ajh.26142.
    PubMed     Abstract available


  120. DAVER N, Salhotra A, Brandwein JM, Podoltsev NA, et al
    A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.
    Am J Hematol. 2021 Feb 22. doi: 10.1002/ajh.26136.
    PubMed    


  121. VENUGOPAL S, Maiti A, DiNardo CD, Loghavi S, et al
    Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26122.
    PubMed    


  122. WANG S, Wang X, Ye C, Cheng H, et al
    Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26123.
    PubMed    


  123. BEGNA KH, Gangat N, Al-Kali A, Litzow MR, et al
    Acute myeloid leukemia after age 70 years: a retrospective comparison of survival following treatment with intensive vs HMA +/- venetoclax chemotherapy.
    Am J Hematol. 2021 Feb 2. doi: 10.1002/ajh.26112.
    PubMed    


  124. ZHENG H, Mineishi S, Claxton D, Zhu J, et al
    A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.
    Am J Hematol. 2021;96:E46-E50.
    PubMed    


    January 2021
  125. RICHARDSON DR, Swoboda DM, Moore DT, Johnson SM, et al
    Genomic Characteristics and Prognostic Significance of Co-mutated ASXL1/SRSF2 Acute Myeloid Leukemia.
    Am J Hematol. 2021 Jan 27. doi: 10.1002/ajh.26110.
    PubMed     Abstract available


  126. HERGOTT CB, Dal Cin P, Hornick JL, Winer ES, et al
    Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion.
    Am J Hematol. 2021 Jan 25. doi: 10.1002/ajh.26107.
    PubMed    


  127. JONAS BA, Fisch SC, Rosenberg AS, Hoeg RT, et al
    Phase I Study of Escalating Doses of Carfilzomib with HyperCVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
    Am J Hematol. 2021 Jan 21. doi: 10.1002/ajh.26105.
    PubMed    


    December 2020
  128. BROWN JR, Walker SR, Heppler LN, Tyekucheva S, et al
    Targeting Constitutively Active STAT3 in Chronic Lymphocytic Leukemia: A Clinical Trial of the STAT3 Inhibitor Pyrimethamine with Pharmacodynamic Analyses.
    Am J Hematol. 2020 Dec 29. doi: 10.1002/ajh.26084.
    PubMed    


  129. CORTES JE, Mehta P
    Determination of Fitness and Therapeutic Options in Older Patients With Acute Myeloid Leukemia.
    Am J Hematol. 2020 Dec 23. doi: 10.1002/ajh.26079.
    PubMed     Abstract available


  130. WANG HP, Zhou YL, Huang X, Zhang Y, et al
    CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.
    Am J Hematol. 2020 Dec 11. doi: 10.1002/ajh.26069.
    PubMed     Abstract available


  131. TESTI AM, Canichella M, Vitale A, Piciocchi A, et al
    Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase ii pediatric-like gimema lal-1308 trial.
    Am J Hematol. 2020 Dec 7. doi: 10.1002/ajh.26066.
    PubMed     Abstract available


  132. KOLLER PB, Zhang H, Kantarjian H, Jabbour E, et al
    GATA3 rs3824662A allele is associated with CRLF2 rearranged B-cell acute lymphoblastic leukemia in adults and adolescents and young adults (AYAs) and is associated with poor prognosis.
    Am J Hematol. 2020 Dec 4. doi: 10.1002/ajh.26065.
    PubMed    


  133. MAITI A, Qiao W, Sasaki K, Ravandi F, et al
    Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality.
    Am J Hematol. 2020 Dec 2. doi: 10.1002/ajh.26061.
    PubMed     Abstract available


  134. DIAO S, Nichols ED, DiNardo C, Konopleva M, et al
    Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax.
    Am J Hematol. 2020 Dec 1. doi: 10.1002/ajh.26060.
    PubMed    


  135. PATEL S, Nayernama A, Jones SC, de Claro RA, et al
    BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
    Am J Hematol. 2020;95:E332-E335.
    PubMed    


  136. SASAKI K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, et al
    Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
    Am J Hematol. 2020;95:E326-E329.
    PubMed    


  137. OFORI K, Soderquist CR, Murty VV, Park D, et al
    The clinical and pathological features of plasma cell myeloma post solid organ transplantation.
    Am J Hematol. 2020;95:1531-1541.
    PubMed     Abstract available


    November 2020
  138. ARSLAN S, Zhang J, Dhakal P, Moran J, et al
    Outcomes of Therapy with Venetoclax Combined with A Hypomethylating Agent in Favorable-Risk Acute Myeloid Leukemia.
    Am J Hematol. 2020 Nov 23. doi: 10.1002/ajh.26057.
    PubMed    


  139. SASAKI K, Jabbour EJ, Ravandi F, Konopleva M, et al
    The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes.
    Am J Hematol. 2020 Nov 12. doi: 10.1002/ajh.26047.
    PubMed     Abstract available


  140. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, et al
    Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2020 Nov 6. doi: 10.1002/ajh.26044.
    PubMed    


  141. GARCIA-MANERO G, Chien KS, Montalban-Bravo G
    Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Am J Hematol. 2020;95:1399-1420.
    PubMed     Abstract available


  142. MANNELLI F, Gianfaldoni G, Bencini S, Piccini M, et al
    Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.
    Am J Hematol. 2020;95:1304-1313.
    PubMed     Abstract available


    October 2020
  143. POLLYEA DA, Pratz K, Letai A, Jonas BA, et al
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study.
    Am J Hematol. 2020 Oct 29. doi: 10.1002/ajh.26039.
    PubMed     Abstract available


  144. BRANDWEIN JM, Hallett D, Karkhaneh M, Zhu N, et al
    An Evaluation of No-Treatment Decisions in Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2020 Oct 6. doi: 10.1002/ajh.26012.
    PubMed    


  145. RAUTENBERG C, Germing U, Stepanow S, Lauseker M, et al
    Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia.
    Am J Hematol. 2020 Oct 5. doi: 10.1002/ajh.26013.
    PubMed    



  146. Abstracts from the 2020 Lymphoma, Leukemia and Myeloma Congress October 21-24, 2020.
    Am J Hematol. 2020;95 Suppl 1:S3-S38.
    PubMed    


    September 2020
  147. POIANI M, Labopin M, Battipaglia G, Beelen DW, et al
    The impact of cytogenetic risk on the outcomes of Allogeneic Hematopoietic Cell Transplantation in patients with relapsed/refractory acute myeloid leukemia: on behalf of the Acute Leukemia Working Party (ALWP) of the EBMT.
    Am J Hematol. 2020 Sep 17. doi: 10.1002/ajh.26000.
    PubMed     Abstract available


  148. MARZOLLO A, Maestrini G, La Starza R, Elia L, et al
    A novel germline variant in PIK3R1 results in SHORT syndrome associated with TAL/LMO T-cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2020 Sep 16. doi: 10.1002/ajh.25998.
    PubMed    


  149. CHO BS, Min GJ, Park S, Park SS, et al
    Haploidentical versus matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study.
    Am J Hematol. 2020 Sep 9. doi: 10.1002/ajh.25993.
    PubMed     Abstract available


  150. BARON F, Labopin M, Ruggeri A, Sierra J, et al
    Impact of detectable measurable residual disease on umbilical cord blood transplantation.
    Am J Hematol. 2020;95:1057-1065.
    PubMed     Abstract available


  151. SMITH CJ, Kluck LA, Ruan GJ, Ashrani AA, et al
    The differential diagnosis of basophilia in patients undergoing BCR-ABL testing.
    Am J Hematol. 2020;95:E216-E217.
    PubMed    


  152. MARGOLSKEE E, Pillai V
    Loss of surface CD3 expression in allogeneic CAR T-cells.
    Am J Hematol. 2020;95:1115-1116.
    PubMed    


    August 2020
  153. PAGNANO KBB, Lopes ABP, Miranda EC, Delamain MT, et al
    Efficacy and Safety of Pioglitazone in a Phase 1/2 Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia with Deep Molecular Response.
    Am J Hematol. 2020 Aug 30. doi: 10.1002/ajh.25986.
    PubMed    


  154. VAN ELSSEN CHMJ, Ciurea SO
    NK Cell Alloreactivity in Acute Myeloid Leukemia in the Post-transplant Cyclophosphamide Era.
    Am J Hematol. 2020 Aug 28. doi: 10.1002/ajh.25983.
    PubMed     Abstract available


  155. MORSIA E, McCullough K, Joshi M, Cook J, et al
    Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25978.
    PubMed     Abstract available


  156. ESTEY EH
    Acute myeloid leukemia: 2021 update on risk-stratification and management.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25975.
    PubMed    


  157. SANDBERG Y, Verhoeven GT, Weerkamp F, Broyl A, et al
    Primary plasma cell leukemia mimicking a Pancoast tumor.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25977.
    PubMed    


  158. PLEYER C, Tian X, Rampertaap S, Mu R, et al
    A Phase II Study of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia.
    Am J Hematol. 2020 Aug 18. doi: 10.1002/ajh.25968.
    PubMed    


  159. CANDONI A, Lazzarotto D, Ferrara F, Curti A, et al
    Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma. the campus-all study.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25957.
    PubMed     Abstract available


  160. SAYGIN C, Larkin K, Blachly JS, Orwick S, et al
    A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25958.
    PubMed     Abstract available


  161. JONDREVILLE L, Krzisch D, Chapiro E, Nguyen-Khac F, et al
    The complex karyotype and chronic lymphocytic leukemia. A review of the literature.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25956.
    PubMed     Abstract available


  162. JENG MY, Dutta R, Tan IT, Zhang TY, et al
    Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies.
    Am J Hematol. 2020 Aug 3. doi: 10.1002/ajh.25949.
    PubMed    


  163. KOFFMAN B, Mato A, Byrd JC, Danilov A, et al
    Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts.
    Am J Hematol. 2020;95:E199-E203.
    PubMed    


  164. PATNAIK MM, Lasho T, Padron E, McCullough K, et al
    Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic.
    Am J Hematol. 2020;95:E203-E208.
    PubMed    


    July 2020
  165. BORTHAKUR G, Zeng Z, Cortes JE, Chen HC, et al
    Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
    Am J Hematol. 2020 Jul 22. doi: 10.1002/ajh.25943.
    PubMed     Abstract available


  166. ABAZA Y, Kantarjian H, Alwash Y, Borthakur G, et al
    Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia.
    Am J Hematol. 2020 Jul 18. doi: 10.1002/ajh.25939.
    PubMed     Abstract available


  167. DHOLARIA B, Labopin M, Angelucci E, Ciceri F, et al
    Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia.
    Am J Hematol. 2020 Jul 13. doi: 10.1002/ajh.25934.
    PubMed     Abstract available


  168. ALDOSS I, Zhang J, Mei M, Al Malki MM, et al
    Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
    Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25929.
    PubMed     Abstract available


  169. COLADO A, Marin Franco JL, Elias EE, Amondarain M, et al
    Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils.
    Am J Hematol. 2020;95:E174-E178.
    PubMed    


  170. KIM GYG, Burns J, Freyer CW, Hamilton KW, et al
    Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
    Am J Hematol. 2020;95:792-798.
    PubMed     Abstract available


    June 2020
  171. BOCK AM, Pollyea DA
    Venetoclax with Azacitidine for Two Younger Jehovah's Witness Patients with High Risk Acute Myeloid Leukemia.
    Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25916.
    PubMed    


  172. DAGA S, Rosenberger A, Kashofer K, Heitzer E, et al
    Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
    Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25918.
    PubMed     Abstract available


  173. OHANIAN M, Kantarjian HM, Shoukier M, Dellasala S, et al
    The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia.
    Am J Hematol. 2020 Jun 17. doi: 10.1002/ajh.25907.
    PubMed     Abstract available


  174. IURLO A, Cattaneo D, Malato A, Accurso V, et al
    Low-Dose Ponatinib Is A Good Option In Chronic Myeloid Leukemia Patients Intolerant To Previous Tkis.
    Am J Hematol. 2020 Jun 17. doi: 10.1002/ajh.25908.
    PubMed    


  175. RUAN GJ, Smith CJ, Day C, Harmsen WS, et al
    A Population-based Study of Chronic Eosinophilic Leukemia-Not Otherwise Specified in the United States.
    Am J Hematol. 2020 Jun 13. doi: 10.1002/ajh.25906.
    PubMed    


  176. HASTINGS A, Apperley JF, Nadal-Melsio E, Brown L, et al
    Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13).
    Am J Hematol. 2020 Jun 10. doi: 10.1002/ajh.25903.
    PubMed    


  177. JAIN P, Wang XI
    Carcinocythemia - cancer cell leukemia.
    Am J Hematol. 2020 Jun 10. doi: 10.1002/ajh.25902.
    PubMed    


  178. SAMRA B, Alotaibi AS, Short NJ, Khoury JD, et al
    Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Am J Hematol. 2020 Jun 5. doi: 10.1002/ajh.25896.
    PubMed    


  179. SUNG AD, Jauhari S, Siamakpour-Reihani S, Rao AV, et al
    Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
    Am J Hematol. 2020;95:662-671.
    PubMed     Abstract available


  180. PATEL SS, Weinberg OK
    Diagnostic workup of acute leukemias of ambiguous lineage.
    Am J Hematol. 2020;95:718-722.
    PubMed     Abstract available


    May 2020
  181. QASRAWI A, Ramlal R, Munker R, Hildebrandt GC, et al
    Prognostic impact of Philadelphia Chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome.
    Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25873.
    PubMed     Abstract available


  182. BYRNE M, Danielson N, Sengsayadeth S, Rasche A, et al
    The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
    Am J Hematol. 2020 May 10. doi: 10.1002/ajh.25859.
    PubMed     Abstract available


  183. AITKEN MJL, Benton CB, Wang F, Zhang J, et al
    33 years later: Two distinct cases of acute lymphoblastic leukemia in one patient.
    Am J Hematol. 2020 May 1. doi: 10.1002/ajh.25850.
    PubMed    


    April 2020
  184. SHORT NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, et al
    Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
    Am J Hematol. 2020 Apr 30. doi: 10.1002/ajh.25854.
    PubMed    


  185. CADENAS FL, Bua BR, Campelo MD, Rieu JB, et al
    A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25842.
    PubMed    


  186. CHRISTIAN S, Arain S, Patel P, Khan I, et al
    A Multi-institutional Comparison of Mitoxantrone, Etoposide, and Cytarabine (MEC) versus High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25838.
    PubMed     Abstract available


  187. MAFFINI E, Labopin M, Blaise D, Ciceri F, et al
    CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the Euro
    Am J Hematol. 2020 Apr 17. doi: 10.1002/ajh.25826.
    PubMed     Abstract available


  188. KLEINSTERN G, O'Brien DR, Li X, Tian S, et al
    Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.
    Am J Hematol. 2020 Apr 12. doi: 10.1002/ajh.25831.
    PubMed     Abstract available


  189. GIARDINO S, Peffault de Latour R, Aljurf M, Eikema DJ, et al
    Outcome of Patients with Fanconi Anemia developing myelodysplasia and acute leukemia who received Allogeneic Hematopoietic Stem Cell Transplantation: A retrospective analysis on Behalf of EBMT group.
    Am J Hematol. 2020 Apr 8. doi: 10.1002/ajh.25810.
    PubMed     Abstract available


  190. ROGERS HJ, Wang X, Xie Y, Davis AR, et al
    Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a Bone Marrow Pathology Group study.
    Am J Hematol. 2020 Apr 6. doi: 10.1002/ajh.25814.
    PubMed     Abstract available


  191. MORSIA E, Reichard K, Pardanani A, Tefferi A, et al
    WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25811.
    PubMed    


  192. ZHU HH, Yang MC, Wang F, Lou YJ, et al
    Identification of a novel NUP98-RARA fusion transcript as the 14(th) variant of acute promyelocytic leukemia.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25807.
    PubMed    


  193. LOSCOCCO GG, Mannelli F, Mannelli L, Vergoni F, et al
    A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: morphological and molecular characteristics of a highly aggressive disease.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25806.
    PubMed    


  194. KEMPS PG, Cleven AHG, van Wezel T, van Eijk R, et al
    B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25801.
    PubMed    


  195. JABBOUR E, Kantarjian H
    Chronic Myeloid Leukemia: 2020 Update on Diagnosis, Therapy and Monitoring.
    Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25792.
    PubMed     Abstract available


  196. OHANIAN M, Telouk P, Kornblau S, Albarede F, et al
    A heavy metal baseline score predicts outcome in acute myeloid leukemia.
    Am J Hematol. 2020;95:422-434.
    PubMed     Abstract available


  197. COLTRO G, Antelo G, Lasho TL, Finke CM, et al
    Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Am J Hematol. 2020;95:E86-E89.
    PubMed    


    March 2020
  198. BARON F, Efficace F, Cannella L, Muus P, et al
    Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: Long-term follow up of a phase III study.
    Am J Hematol. 2020 Mar 31. doi: 10.1002/ajh.25795.
    PubMed     Abstract available


  199. GARCIA JS, Bhatt S, Fell G, Sperling AS, et al
    Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
    Am J Hematol. 2020;95:245-250.
    PubMed     Abstract available


    January 2020
  200. WILLIAMS AM, Baran AM, Schaffer M, Bushart J, et al
    Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
    Am J Hematol. 2020;95:E16-E18.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: